Upstream Bio Launches with $200M Series A Financing to Advance Novel Therapeutics for Allergic and Inflammatory Diseases

Clinical-stage program UPB-101 targets the TSLP receptor, a cytokine receptor positioned upstream in the inflammatory cascade with the potential to impact multiple diseases, including asthma